Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

MLA

Yoon Jin Choi, et al. “Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter Pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.” Gut and Liver, vol. 16, no. 4, July 2022, pp. 535–46. EBSCOhost, https://doi.org/10.5009/gnl220055.

APA

Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, Byoung Kwan Son, Hang Lak Lee, Kyoung Oh Kim, Nayoung Kim, Kwang Hyun Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Jai Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, … Jae Young Jang. (2022). Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut and Liver, 16(4), 535–546. https://doi.org/10.5009/gnl220055

Chicago

Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, et al. 2022. “Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter Pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.” Gut and Liver 16 (4): 535–46. doi:10.5009/gnl220055.